Abstract The terminal monosaccharide of glycoconjugates on a eukaryotic cell surface is typically a sialic acid (Neu5Ac). Increased sialylation usually indicates progression and poor prognosis of most carcinomas. Here, we utilize two human mammary epithelial cell lines, HB4A (breast normal cells) and T47D (breast cancer cells), as a model system to demonstrate differential surface glycans when treated with sialic acid under nutrient deprivation. Under a starved condition, sialic acid treatment of both cells resulted in increased activities of α2→3/6 sialyltransferases as demonstrated by solid phase assay using lectin binding. However, a very strong Maackia amurensis agglutinin I (MAL-I) staining on the membrane of sialic acid-treated T47D cells was observed, indicating an increase of Neu5Acα2→3Gal on the cell surface. To our knowledge, this is a first report showing the utility of lectins, Appl Biochem Biotechnol (2013) 171:963-974 
Introduction
Protein glycosylation is an important posttranslational modification, which aids in protein folding and cellular secretion [1] . Glycoproteins decorate the cell surface and often sprout sialic acid (Neu5Ac) at the termini of their glycans in a process called sialylation. Glycosylation disorders including increased branching of N-linked glycans and sialylation are major hallmarks of cancer progression [2] . Particularly, over-sialylation on the cell surface induces tumor proliferation by promoting cell detachment from primary tumors through charge repulsion. Despite the potential of variable sialylation as a diagnostic biomarker, there is presently not an early sensing platform to detect glycan sialylation constellations in diverse biological samples with high affinity and sensitivity [3] . However, metabolic engineering of glycan sialylation may have the potential to advance the field of diagnosis and prognosis of cancers.
In order to assess this approach, we note that the selectivity of glycan sialylation is regulated by two factors: (a) metabolic flux through the sialic acid biosynthetic pathway and (b) differential expression level of sialyltransferases [4] . However, neither of these factors has been successfully manipulated with sufficient precision to achieve specific endpoints [5] . Over the past 20 years, glycoengineering approaches have provided new routes for the modulation of glycan structures on cell surfaces [6] . Sugars such as N-acetyl glucosamine, N-acetyl galactosamine, and sialic acid can be metabolically incorporated into glycans through salvage pathways and various constituents of the monitored glycans are studied by "lectins" (a class of carbohydrate-binding proteins) [7] [8] [9] [10] .
In humans, synthesis of Neu5Ac from its precursor, UDP-GlcNAc, takes place primarily in the cytosol through a series of enzymatic reactions [10] . Once Neu5Ac is synthesized, it is incorporated as a nucleotide donor substrate for subsequent transfer to an oligosaccharide structure. This substrate creation takes place in the nucleus, where Neu5Ac is attached to cytidine 5′-triphosphate (CTP) to produce the donor substrate CMP-Neu5Ac by the enzyme CMP-Neu5Ac synthetase. The CMP-Neu5Ac substrate is then transported to the cytoplasm and then to the Golgi for use by the sialyltransferases (ST), which attach Neu5Ac residues to oligosaccharides through various linkages such α2→3, α2→6, or α2→8 [11] .
Although Neu5Ac and CMP-sialic acid are the most abundant immediate precursors for glycan sialylation, both offer poor cell membrane permeability. Thus, feeding of either of these sialylation precursors does not increase the intracellular pool of CMP-sialic acid [12] .
Recent data indicate that the cell surface glycoengineering is often compromised by the cell membrane and, thus, can be significantly enhanced by treating the cell membrane [13, 14] . We therefore strongly suggest that stimulation of the cell membrane by the intermediate precursors for glycan sialylation through specific metabolic conditioning may allow engineering of sialoglycan metabolism and produce a distinct set of changes in glycan sialylation. In this paper, we examine the over-sialylation of cell surface glycans in a sialic acid fed-batch culture system without adequate nutrients and employing sialic acid binding lectins to probe global differences in cell surface sialylation. We chose breast normal cells (HB4A) and breast cancer cells (T47D) because they have proven to be ideal model systems for studying protein glycosylation in health and disease state [15, 16] . Our method is sensitive and allows selective detection of glycan sialylation on a cancer cell surface affording new potential applications for the study of cancer diagnosis and prognosis.
Materials and Methods
Materials Sialic acid (N-acetyl-5-neuraminic acid, Neu5Ac), asialofetuin, CMP-Neu5Ac, ribonuclease A, insulin, hydrocortisone, RPMI1640 medium, and phosphate-buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, pH 7.4) were purchased from Sigma-Aldrich, USA. Maackia amurensis agglutinin I (MAL-I) specific for Neu5Acα2,3Gal, Sambucus nigra agglutinin (SNA) specific for Neu5Acα2,6Gal, Triticum vulgaris agglutinin (WGA) specific for Neu5Ac and GlcNAc, streptavidin-horseradish peroxidase, and biotinylated MAL-I and SNA lectins were obtained from Vector Laboratories (USA). Fetal bovine serum (FBS) was from Biosera (USA). TO-PRO-3 was obtained from Molecular Probes (USA).
Cell Culture Human normal mammary epithelial cell line HB4A and breast cancer cell line T47D (American Type Culture Collection, USA) were cultured in RPMI1640 medium supplemented with 1 % FBS at 37°C under 5 % CO 2 . For HB4A cells, the medium also contained 10 μg/mL insulin and 5 μg/mL hydrocortisone. For all experiments, HB4A and T47D cells were used within the first three passages and cells were harvested by treatment with 5 mL of buffer containing 0.54 mM EDTA, 154 mM NaCl, and 10 mM HEPES, pH 7.4 for <5 min at 37°C.
Sialic Acid Treatment Cells were grown for 48 h and harvested in the indicated conditions. Cells were then resuspended in serum-free RPMI 1640 medium. After washing three times with warm (37°C) PBS, 20 mL of cell suspension was treated with 10 mM sialic acid in PBS for 2 h in shake flasks in a 37°C incubator under 5 % CO 2 . Control cells included only PBS. The cells were plated at a density of 3×10 5 cells mL −1
. After washing, the cells were fixed in 75 % ice-cold ethanol for 15 min and maintained at 4°C for experiments. For negative controls, cells were also treated with sialic acid in serum containing medium and harvested as described above.
Cell Viability Cells were harvested as described above without fixation. Cell pellets were resuspended in PBS supplemented with 1 mg/mL propidium iodide (PI) and incubated for 5 min at ambient temperature. Cells were analyzed by flow cytometry on a CyAn™ ADP flow cytometer (Beckman Coulter Inc., USA). The dead cell population was determined as the percentage of PI-stained cells. MTT assay was used to determine the viability of cells for 5 days after returning the SA-treated and untreated cells to the complete medium. The formazan dye produced after DMSO solubilization was evaluated at 560 nm by a multiwell scanning spectrophotometer (Bio-Rad, USA).
Quantification of Membrane-Bound Sialic Acid PBS-washed cells ( 1×10 6 ) were lysed by hypotonic shock in 1 mL water (15 min, 4°C). The crude membrane fraction was pelleted by centrifugation at 10,000×g for 15 min. The pellet was washed twice with water and lyophilized. The sialic acid content of the membrane fraction was determined by acid hydrolysis followed by 1,2-diamino-4,5-methylenedioxybenzene (DMB) derivatization and high-performance liquid chromatography (HPLC) separation as previously described [17] . Briefly, sialic acids were released from lyophilized fractions by acid hydrolysis with 2 M acetic acid for 3 h at 80°C. Samples were passed through a Microcon-10 filter and the filtrate was derivatized with DMB for analysis of sialic acids by HPLC (PerkinElmer, USA). Separation of DMB-labeled sialic acids was performed on a Shim-pack CLC-ODS (6.0×150 mm) column using a mobile phase of acetonitrile-methanol-water (9:7:84, v/v) with a flow rate of 1 mL/min at 22°C and detected using an emission wavelength of 448 nm and an excitation wavelength of 373 nm.
Detection of Sialyltransferase Activity The activity of ST3Gal-I and ST6Gal-I was determined by solid phase assay using asialofetuin-precoated plates as previously described [18] . Briefly, various cell lysates containing equal amount of protein were taken into the wells and CMP-Neu5Ac was added to initiate the reaction. After washing and blocking, the sialylated fetuin was allowed to interact with either biotinylated lectin (MAL-I or SNA) followed by binding with streptavidin-horseradish peroxidase. The negative control included only lectin binding to asialofetuin. After binding and washing, the reaction was developed with 100 μL solution of substrate (0.03 % H 2 O 2 , 2 mg/mL o-phenylenediamine in 0.1 mM citrate buffer, pH 5.5) for ∼10 min and terminated with 1 M H 2 SO 4 . The absorbance at 492 nm was measured using an automatic multiwell spectrophotometer (Bio-Rad, USA).
Gene Expression Analyses by RT-PCR and Quantitative RT-PCR Total RNA was extracted from cells using TRIzol reagent and 1 μg of total RNA was reverse transcribed to cDNA using the GoScript™ Reverse Transcription System (Promega, USA). The resulting cDNA was amplified in triplicate using GoTaq qPCR Master Mix (Promega, USA) on a Real-Time PCR System (Applied Biosystems, USA). β-Actin was used as the internal control. The relative expression levels were analyzed in Microsoft Excel using the comparative 2 −ΔΔCT method as per the instructions of the manufacturer (Applied Biosystems). The primer sequences for ST3Gal-I and ST6Gal-I were previously reported [19] .
Flow Cytometric Analysis Cells were fixed with 75 % ice-cold ethanol for 15 min, washed twice with cold PBS, and placed in 96-well plates (1×10 4 cells per well). The cells were then stained with the fluorescein isothiocyanate-labeled lectins (MAL-I, SNA, and WGA). For the comparison of mean fluorescence intensities, the instrument settings for fluorescence and compensation were the same for all experiments. Data were collected from at least 10,000 cells for each sample.
Lectin Staining and Confocal Microscopy Cells were grown in six-well plates and the adherent cells were then fixed with 75 % ice-cold ethanol for 15 min. After washing, the fixed cells were stained with various lectin conjugates (10 μg/mL) in 0.05 M Tris-buffered saline, 1 mM CaCl 2 , and 1 mM MgCl 2 , pH 7.6, for 1 h. After staining, cells were further treated with ribonuclease A (50 μg/mL) and the nuclei were counter stained with TO-PRO-3. Images were acquired by sequential scanning using a Leica TCS SP2 confocal system (Leica Microsystems, Milton Keynes, UK) and an X63 ceramic dipping objective at 1,024×1,024 format and scanning speed of 400 Hz with a line average of 2. A 488-nm (intensity 25 %) laser was used for the excitation of fluorescein isothiocyanate (FITC) and a 633-nm laser (intensity 35 %) was used for TO-PRO-3. Emission was recorded over the bandwidth of 500-550 nm (FITC) and 650-720 nm (TO-PRO-3).
Statistical Analysis Data are expressed as the mean S.E. for at least three independent experiments. Statistical significance of differences between means was determined by analysis of variance. The differences were considered significant when p<0.05.
Results

Effects of Sialic Acid Treatment on the Cell Viability
To investigate if sialic acid treatment affects cell viability under nutrient-deprived condition, cells were stained with PI and analyzed on a flow cytometry (Fig. 1a) . Using a fixed number of cells (3×10 5 cells mL
), the percentage of viable cells was 93.45 and 95.27 % for untreated HB4A and T47D cells (PBS control), respectively (Fig. 1b) . For sialic acid-treated cells, the cell viability was 94.16 and 96.05 % for HB4A and T47D, respectively (see Fig. 1b) . Moreover, the cell proliferation ability of each treated and untreated cell line (when the cells were put back into the complete medium after 2 h nutrient-deprived condition) was also unchanged as demonstrated by the MTT assay (Supplementary (Suppl.) Fig. 1 ), suggesting that the exposure to sialic acid at the indicated conditions did not affect cell viability.
Effects of Sialic Acid Treatment on Cell Membrane Composition
The sialic acid content of the membrane fraction was determined by acid hydrolysis on HPLC. The untreated T47D cancer cells (2.39 nM/10 6 cells) contain more membrane-bound sialic acid as compared to HB4A normal cells (1.29 nM/10 6 cells) (Fig. 2a and Suppl. Fig. 2A ). The membrane-bound sialic acid is further increased in both cell types when treated with sialic acid under nutrient-deficient condition (2.75 nM/10 6 HB4A sialic acidtreated cells, p<0.001, and 3.98 nM/10 6 T47D sialic acid-treated cells, p<0.001) (Fig. 2a and Suppl. Fig. 2A) . The results clearly demonstrated the increase of cell membrane-bound sialic acid upon sialic acid treatment at nutrient-deprived condition.
Influence of Sialic Acid Treatment on the Sialyltransferase Activity
To investigate if sialic acid treatment under nutrient-deprived condition influences sialyltransferase activity, cell extract was incubated with asialofetuin (acts as acceptor) and the resultant sialo-fetuin was quantitated with linkage specific lectins as described in the experimental procedures. Results showed that both α2→3 sialyltransferase (ST3Gal-I) and α2→6 sialyltransferase (ST6Gal-I) activities were present in HB4A and T47D cells as demonstrated by positive binding with MAL-I and SNA binding (Fig. 2b) . As expected, negative control (lectin binding to asialofetuin only) resulted no binding or in negligible binding (not shown). Interestingly, sialic acid treatment of HB4A and T47D cells increased ST3Gal-I activity as measured by MAL-I binding by 60 % (p<0.001) and 45 % (p<0.001), respectively. Similarly, ST6Gal-1 activity of the sialic acid-treated HB4A and T47D cells as measured by SNA binding was increased by 37 % (p<0.001) and 25 % (p<0.001), respectively. To determine whether the increase in the sialic acid is related to gene expression profiles, we examined the mRNA expression levels of sialyltransferases by quantitative RT-PCR. The mRNA expression level of ST3Gal-I and ST6Gal-I in sialic acid-treated cells was also increased at least 1.5-to 4-fold when compared to the corresponding untreated cells (Fig. 2c and Suppl. Fig.2B ). Together, these results show that sialic acid treatment under nutrient-deficient condition increased the expression of α2→3 sialyltransferase (ST3Gal-I) and α2→6 sialyltransferase (ST6Gal-I).
Cell Surface Sialoglycoconjugate Changes
To examine if sialic acid treatment could influence the display of specific sialoglycans, we performed cell binding of SA-treated and untreated cells (with and without nutrient) with FITC-conjugated lectins (MAL-I, SNA, and WGA) on a flow cytometer (Fig. 3a) . We found that sialic acid treatment under nutrient deprivation promotes differential expression of cell Mean Fluorescence Intensity NS not significant surface sialoglycoconjugates and reveals the utility of MAL-I lectin binding as a means to discriminate between normal and cancer cells. In the case of SA treatment under nutrient deprivation, both normal (HB4A) and cancer (T47D) cells display sialoglycoconjugates as measured by the above lectin-FITC binding (Fig. 3a, b) . As expected, no binding was observed with FITC alone with either cell (normal or cancer, untreated or treated) (Suppl. (Fig. 3b) . Conversely, decreased lectin binding (as maximum as mean fluorescence intensity 218) was observed on the surface of both normal and cancer cells when treated with sialic acid for 48 h under nutrient full medium (Suppl. Fig. 4) . We next performed lectin staining of the cells followed by confocal assessment. In both normal and cancer cells, FITC-conjugated WGA and SNA lectins showed a strong fluorescence signal, which was further enhanced in sialic acid-treated cells (Fig. 4) . However, a very weak staining was observed with MAL-I lectin in the untreated HB4A and T47D cells. Consistent with flow analyses, sialic acid-treated normal cells showed a slight increase in MAL-I staining, but a very strong staining was observed in sialic acid-treated cancer cells (see Fig. 4 ). MAL-I-binding of sialic acid-treated cancer cells, as revealed through either flow analysis or confocal imaging, suggests that cancer cells, upon sialic acid treatment, differentially display Neu5Acα2→3Gal, which makes the cancer cells distinguishable from the normal cells.
Discussion
Cancer cell has properties different than the normal cell in growth, division, and death. Cancer cell must reprogram cellular metabolism to satisfy the demands of growth and persistence. The rapid cancer cell growth is also fundamentally dependent upon generating a metabolic condition that satisfies the sum of these requirements. Ultimately, efforts to unravel metabolic alterations may enable the identification of novel therapeutic and diagnostic targets [20, 21] . Our approach is useful when seeking to differentiate sialylation epitopes that are quantitative or linkage specific through the glycan sialylation expression on a tumor cell surface arising from altered metabolism. Therefore, comparative studies of the expression levels of glycan sialylation in normal and cancer cells in a specific metabolic conditioning might aid in the understanding of their roles in cancer development and help to improve cancer diagnosis, prognosis, and treatment.
Here we showed the treatment of nutrient-deprived cells with sialic acid-enhanced sialyltransferase activities. The enhanced sensitivity of these enzymes is reflected through dysregulation of sialoglycan metabolism during breast cancer transformation and progression. Overexpression of sialyltransferases and increased sialylation in breast cancer cells, relative to nonmalignant cells, has been documented [22] . Increased sialylation on the cell surface promotes cell detachment from primary tumors through charge repulsion, thereby inducing tumor proliferation and migration [23] . Recently, the overexpression of ST3Gal-I has been shown to promote mammary tumorigenesis in transgenic mice [24] . Moreover, the expression of α2→6 sialyltransferase I (ST6GalNAc-I) in MDA MB231 breast cancer cells enhances the tumorigenicity of breast cancer cells [25] .
Treatment of nutrient-deprived cells, particularly cancer cells with sialic acid, resulted in enhanced binding with the sialic acid-specific lectins as demonstrated in two settings: flow analysis and confocal imaging. The examined lectins are distributed mostly in the cell surface and partly in the cytoplasm. Confocal imaging of the lectins, particularly MAL-I and SNA, confirmed a membrane-associated fluorescence. Therefore, the increase of SNA and MAL-I staining can be attributed to an increase of sialic acids on the outer leaflet of the cellular membranes [26] . Previous studies have reported that MAL-I, SNA, and WGA recognize sialic acid on the terminal branches [27, 28] . In particular, MAL-I detects glycans containing Neu5Ac-Gal-GlcNAc with sialic acid at the 3 position of galactose, while SNA binds preferentially to sialic acid attached to terminal galactose in α2→6 and, to a lesser degree, in α2→3 linkage. WGA binds to almost all the isomers of sialylated glycans where its signal translates into a general level of sialylation. This is consistent with the observation that both untreated cells normally show abundant α2→6-linked sialic acid, whereas terminal α2→3-linked sialic acid residues are highly restricted. More importantly, comparison of the treated cells profiles revealed that T47D cells enforced a much broader range of α2→3-and α2→6-sialylated glycans compared with those in HB4A cells which expressed a high level of α2→6-sialylated glycans and retained restrictions of α2→3-sialylated glycans. Thus, the results of the current study suggest that Neu5Ac treatment promotes the display of α2→3-sialylated glycans structures on the surface of cancer cells and not on those of normal cells. To our knowledge, this is the first report showing that lectins, in particular MAL-I, can be used in a metabolic-specific manner to discriminate between normal and cancer glycans positioning this approach for rapid translation to clinical settings. The result is significant as this approach can be applied to identify and quantitate circulating tumor cells for prognosis or therapeutic management of cancer. However, a larger number of cancer cell lines must be investigated to determine the breadth of this conclusion. Overall, our findings will enable the development of additional sialic acid engineering strategies essential for cancer diagnostic product development and optimization.
